Sana Karam, MD, PhD

1.9K posts

Sana Karam, MD, PhD banner
Sana Karam, MD, PhD

Sana Karam, MD, PhD

@KaramLab

Tumor Immunology, TME, Systemic Immunity, Radiation Oncology, Wash U

Saint Louis, MO Beigetreten Kasım 2020
604 Folgt1.7K Follower
Sana Karam, MD, PhD
Sana Karam, MD, PhD@KaramLab·
@TejasPatilMD @lcsmchat We must be careful, especially in medicine and when dealing with patients and human life. Undoubtedly the system needs fixing. Unsure though that SM or AI are the fix…
English
0
0
3
247
Tejas Patil
Tejas Patil@TejasPatilMD·
🙌🏾 PREACH. With social media & rapid dissemination of data, the value of “high impact” will disappear. ⭐️My view: just get the data out there, quickly (eg BioRxViv) ❤️ Love suggestion of experimenting with AI. Relying on editorial goodwill is NOT sustainable. @lcsmchat @OncoAlert @OncLive @OncogeneCancer @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchKate
Ruslan Rust@rust_ruslan

I currently have three papers in review at "high impact" journals. One of them has been sitting there for two years. In that time my daughter was born and learned how to walk, but apparently publishing a PDF was still not possible for me. For another one, after four months in review the editor told me they cannot find a second reviewer and asked me to suggest more reviewers. A third one sent me a message in 2026 saying the PDF I uploaded was larger than 10 MB and that I should please reupload everything to make the file smaller. All of this just to eventually pay between 7,000 and 12,000 USD per paper so someone can officially approve that the science we do is "legitimate". Reminder: not a single reviewer will be compensated here. I still don't understand how we as scientists can collectively be so smart when doing science and still tolerate a system like this when it comes to sharing our findings. We should move to preprints plus open review, whether human or AI, asap. So frustrated about it. I'd suggest sharing your work on bioRxiv or medRxiv, reading and reviewing preprints when you can, and highlighting good research, especially if it is still a preprint. Try platforms like ResearchHub (that pay for peer review) and experiment with AI based reviewers for faster feedback. Instead I read this as a proposed "revolutionary" measure:

English
3
1
9
1.4K
Sana Karam, MD, PhD retweetet
Melvin LK CHUA | FRCR, PhD, FASCO
7y in the making!!! As I always spoke about this, the field of #NasopharyngealCarcinoma leads the way in driving individualised treatment in #HeadNeckCancer When we published our initial idea of stratifying patients by their early treatment response using #EBVDNA back then in 2018, we decided to test our idea formally with a trial, and kudos to a very talented #biostats and willing collaborators, we came up with EP-STAR Very glad to see it finally published today in @Nature 🍸 nature.com/articles/s4158…
English
5
27
70
5.3K
Sana Karam, MD, PhD retweetet
Denis Wirtz
Denis Wirtz@deniswirtz·
Federal funding for US biomedical research is moribund. Since October 1 2025, NIH is -80% in new grants and -70% in values (total dollars). Labs are closing down and researchers are leaving science. To what end?
Denis Wirtz tweet media
English
43
346
737
175.6K
Sana Karam, MD, PhD retweetet
Anirban Maitra
Anirban Maitra@Aiims1742·
Wonderful news for #PancreaticCancer researchers! The pre-announcement for the @CDMRP Pancreatic Cancer Research Program (PCARP) is online confirming the program is back after a hiatus (Thank you Congress!) Priority areas listed, details to follow! cdmrp.health.mil/pubs/press/202…
English
2
13
44
3.4K
Sana Karam, MD, PhD retweetet
ASTRO
ASTRO@ASTRO_org·
In this #RedJournal article, chemotherapy followed by hypo-fractionated radiotherapy for surgically staged locally advanced endometrial cancer was safe in this early-phase trial. Further research is needed to evaluate whether this can become a standard of care option. @JoshSchiffMD @SilpaCRaju @WashUMedRadOnc tinyurl.com/rjjpschiff
ASTRO tweet media
English
1
12
31
3.2K
Sana Karam, MD, PhD retweetet
Uğur Özkerim
Uğur Özkerim@UOzkerim·
🫁 IO duration in mNSCLC is back in the spotlight. IFCT-1701 “DICIPLE” phase III: 🔹 Stop Nivolumab + Ipilimumab after 6 months vs 🔹 Continue treatment 📊 4-year outcomes: • PFS: NR vs 18.7 months • OS: NR vs 55.5 months • Grade 3–5 AEs: 23.5% vs 54.3% • Better QoL with early stop 💡 Stopping at 6 months → no survival harm, less toxicity. 🧠 Would you stop at 6 months in a controlled mNSCLC patient? @OncoAlert @MedwatchKate @OncoReporte @lungoncdoc @LungSummit @LungCancerEu @StephenVLiu @OncBrothers @GlopesMd @UmbertoMalapel1
Uğur Özkerim tweet media
English
2
24
62
14.8K
Drew Moghanaki
Drew Moghanaki@DrewMoghanaki·
Can we please put to rest the idea that treating lymph nodes helps patients with cancer live longer? Once again, we see no meaningful benefit and only harms—this time in a phase III RCT for bladder cancer. @QuadShotNews nejm.org/doi/10.1056/NE…
Drew Moghanaki tweet mediaDrew Moghanaki tweet media
English
11
26
78
25.7K
Mohammad K. Khan, MD
Mohammad K. Khan, MD@MohammadKhanMD·
@BrendonStilesMD @MHadziMD @DrewMoghanaki @piet_ost @QuadShotNews @_ShankarSiva @KaramLab @AKesarwala @JieDengMDPhD @AmarUKishan @alongi_filippo @fcounago @DrAndrewLoblaw @CharlesSwanton It depends on your goal, and if you know there is disease in the LN or not. LN are a key place of antigen presentation and immune activation. Here is a paper than can shed light on optimizing RT mediate immunity. pubmed.ncbi.nlm.nih.gov/33028691/
English
3
0
2
124
Sana Karam, MD, PhD retweetet
WashU Medicine Radiation Oncology
WashU Medicine Radiation Oncology@WashUMedRadOnc·
We are thrilled to welcome two of our recent #MedicalPhysics residency graduates as our newest faculty members. Nadia Benabdallah, PhD & Austen Curcuru, PhD are fantastic additions to our @SitemanCenter team!
WashU Medicine Radiation Oncology tweet media
English
0
2
9
501
NYU Langone Health
NYU Langone Health@nyulangone·
We’re excited to welcome Daniel Gomez, MD, MBA, a nationally recognized leader in radiation oncology research and clinical trials for lung and oligometastatic cancers, as the new chair of Radiation Oncology at @Perlmutter_CC! Learn more about Dr. Gomez: bit.ly/4rDQliM
NYU Langone Health tweet media
English
5
9
40
4.6K
Sana Karam, MD, PhD retweetet
WashU Medicine Radiation Oncology
WashU Medicine Radiation Oncology@WashUMedRadOnc·
Our inaugural Joseph R Simpson Sr, MD, PhD Research & Education Award winner was announced at last week's @jonykipnis Grand Rounds. We are thrilled to announce PGY2 Varintra Lander, MD, PhD as the winner!! 🎉We look forward to seeing her research progress.
WashU Medicine Radiation Oncology tweet media
English
1
4
17
1.1K